山东沃华医药科技股份有限公司 董事会关于独立董事独立性的专项评估报告 根据《上市公司独立董事管理办法》《深圳证券交易所股票上市 规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市 公司规范运作》等要求，公司独立董事高明芹、王跃生、俞俊利分别 向公司董事会提交了《2024 年度独立董事独立性的自查报告》(以下 简称"自查报告")，山东沃华医药科技股份有限公司（以下简称"公 司"）董事会，对三位独立董事的独立性情况进行评估并出具如下专 项意见： 经对独立董事高明芹、王跃生、俞俊利的任职情况、自查报告及 2024 年度的工作情况进行核查，公司董事会认为，独立董事高明芹、 王跃生、俞俊利不在公司担任除董事、董事会专门委员会委员以外的 其他职务，也未在公司主要股东担任职务，与公司及公司的主要股东、 实际控制人不存在直接或者间接利害关系，也不存在其他可能影响其 进行独立客观判断关系的情况。在 2024 年度的履职过程中，前述独 立董事独立履行职责，不受公司及其主要股东、实际控制人等单位或 者个人的影响，符合《上市公司独立董事管理办法》《深圳证券交易 所上市公司自律监管指引第 1 号——主板上市公司规范运作》 ...

证券代码：002107 证券简称：沃华医药 公告编号：2025-011 山东沃华医药科技股份有限公司 董事会 2024 年度工作报告 2024 年度，公司董事会严格按照《公司法》《证券法》等法律法 规以及《公司章程》《董事会议事规则》等相关规定，本着对全体股 东负责的态度，恪尽职守、积极有效地行使职权，认真执行股东会的 各项决议，勤勉尽责地开展董事会各项工作，保障了公司良好的运作 和可持续发展。现将 2024 年度董事会工作报告如下： 一、公司 2024 年度经营情况 报告期内，公司实现营业收入 76,379.34 万元，同比降低 16.02%； 实现归属于上市公司股东的净利润 3,640.34 万元，同比降低 38.05%。 其中，主要产品线中，心脑血管系统药品营业收入 50,647.98 万元, 同比下降 22.56%；肌肉骨骼系统药品营业收入 18,627.98 万元，同 比下降 0.95%；抗病毒类呼吸系统药品营业收入 2,202.62 万元，同 比增长 24.88%。 2023 年，沃华® 心可舒片进入集采范围，中标价格降低约 39%， 该价格已在 2024 年全面执行。预想中的"以价换量"在 20 ...

证券代码：002107 证券简称：沃华医药 公告编号：2025-018 山东沃华医药科技股份有限公司 关于 2025 年度日常关联交易预计的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 山东沃华医药科技股份有限公司（以下简称"沃华医药"或"公 司"）于 2025 年 4 月 25 日召开第八届董事会第二次会议，审议通 过了《关于 2025 年度日常关联交易预计的议案》，关联董事赵丙贤、 赵彩霞、陈勇、赵丙辉、王炯对该议案回避了表决。该议案在第八届 董事会 2025 年第一次独立董事专门会议审议通过后提交董事会审议。 根据《深圳证券交易所股票上市规则》和《公司章程》等相关规定， 本事项无需提交股东会审议。 一、日常关联交易基本情况 （一）日常关联交易概述 （二）预计日常关联交易类别和金额 单位：万元 1 根据公司业务发展的需要，预计公司 2025 年度可能与关联方通 化卫京药业股份有限公司（以下简称"卫京药业"）发生日常关联交 易，金额预计为 1100 万元。 | | | | 关联 | | 截至披露日 | | | --- | --- | --- | -- ...

证券代码：002107 证券简称：沃华医药 公告编号：2025-014 山东沃华医药科技股份有限公司 2024年度财务决算报告 一、2024 年度公司财务报表的审计情况 1、公司 2024 年财务报表已经永拓会计师事务所（特殊普通合伙）审计，出具了永证审字（2025）第 110017 号标准的无保留意见的审计报告。会计师的审计意见是：本公司的财务报表在所有重大方面按照企业会 计准则的规定编制，公允反映了山东沃华医药科技股份有限公司 2024 年 12 月 31 日合并及母公司的财务 状况以及 2024 年度合并及母公司的经营成果和现金流量。 2、主要财务数据和指标： 单位：元 | 项目 | 2024 年 | 2023 年 | 本年比上年增减 | 2022 年 | | --- | --- | --- | --- | --- | | 营业收入 | 763,793,394.09 | 909,506,771.72 | -16.02% | 1,014,818,455.50 | | 归属于上市公司股东的净利润 | 36,403,379.34 | 58,767,086.78 | -38.05% | 107,385,865. ...

证券代码：002107 证券简称：沃华医药 公告编号：2025-019 山东沃华医药科技股份有限公司 关于召开 2024 年度股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 （一）股东会届次：本次股东会为山东沃华医药科技股份有限公 司 2024 年度股东会。 （二）股东会的召集人：本公司董事会。2025 年 4 月 25 日召开 的第八届董事会第二次会议审议通过了《关于召开 2024 年度股东会 的议案》，同意召集本次股东会。 （三）会议召集的合法、合规性：本次股东会的召集符合有关法 律、行政法规、部门规章、规范性文件和《公司章程》等的规定。 （四）会议召开的日期、时间 1. 现场会议：2025 年 5 月 19 日（星期一）14:00 开始 2. 网络投票：通过深圳证券交易所交易系统进行网络投票的具 体时间为 2025 年 5 月 19日 9:15—9:25，9:30—11:30 和 13:00—15:00； 通过深圳证券交易所互联网投票系统进行网络投票的具体时间为 2025 年 5 月 19 日 9:15 至 2025 ...

山东沃华医药科技股份有限公司 第八届监事会第二次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 证券代码：002107 证券简称：沃华医药 公告编号：2025-010 山东沃华医药科技股份有限公司（以下简称公司）第八届监事会 第二次会议于 2025 年 4 月 25 日以现场加通讯方式召开，会议通知于 2025 年 4 月 14 日以书面、电子邮件等方式发出。本次会议应参会监 事 5 名，实际参会监事 5 名，会议由监事长印文军先生主持。会议的 召开符合《公司法》等相关法律法规及《公司章程》的规定。经与会 监事认真审议，通过了以下决议： 一、会议以 5 票同意，0 票反对，0 票弃权，审议通过了《关 于<公司2024年度监事会工作报告>的议案》。 《山东沃华医药科技股份有限公司 2024 年度监事会工作报告》 刊登在巨潮资讯网（http://www.cninfo.com.cn）供投资者查阅。 二、会议以 5 票同意，0 票反对，0 票弃权，审议通过了《关 于<公司2024年度内部控制评价报告>的议案》。 1 经认真审核，监事会认为：公司已建立了较 ...

证券代码：002107 证券简称：沃华医药 公告编号：2025-009 山东沃华医药科技股份有限公司 第八届董事会第二次会议决议公告 该公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 山东沃华医药科技股份有限公司（以下简称公司）第八届董事会 第二次会议于 2025 年 4 月 25 日以现场加通讯方式召开，会议通知于 2025 年 4 月 14 日以书面、电子邮件等方式发出。本次会议应参会董 事 9 名，实际参会董事 9 名。会议由董事长赵丙贤先生主持。会议的 召开符合《公司法》等相关法律法规及《公司章程》的规定。经与会 董事认真审议，本次会议通过了以下决议： 一、会议以 9 票同意，0 票反对，0 票弃权，审议通过了《关 于<公司2024年度董事会执行委员会工作报告>的议案》。 二、会议以 9 票同意，0 票反对，0 票弃权，审议通过了《关 于<公司 2024 年度董事会工作报告>的议案》。 《山东沃华医药科技股份有限公司 2024 年度董事会工作报告》 刊登在巨潮资讯网（http://www.cninfo.com.cn）供投资者查阅。 公司独立董事高明芹女士 ...

证券代码：002107 证券简称：沃华医药 公告编号：2025-015 山东沃华医药科技股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 山东沃华医药科技股份有限公司（以下称公司）于2025年4月25 日召开第八届董事会第二次会议、第八届监事会第二次会议，审议通 过了《公司2024年度利润分配预案》，该议案尚需提交公司股东会审 议。现将相关事宜公告如下： 二、公司2024年度利润分配预案 经永拓会计师事务所（特殊普通合伙）审计，公司 2024 年度合 并报表归属于上市公司股东的净利润 36,403,379.34 元，扣除根据《公 司法》及《公司章程》规定计提的法定盈余公积金 2,029,638.02 元， 加上年初未分配利润 183,815,215.11 元，减本报告期已分配的 2023 年度利润 144,302,400.00 元 ， 合 并 报 表 可 供 股 东 分 配 利 润 为 73,886,556.43 元。 公司 2024 年度母公司实现净利润 20,296,380.24 元，扣除根据《公 司法》 ...

Financial Performance - The company's operating revenue for 2024 was ¥763,793,394.09, a decrease of 16.02% compared to ¥909,506,771.72 in 2023[6]. - Net profit attributable to shareholders for 2024 was ¥36,403,379.34, down 38.05% from ¥58,767,086.78 in 2023[6]. - The cash flow from operating activities for 2024 was ¥91,509,751.31, representing a decline of 29.20% from ¥129,246,864.39 in 2023[6]. - Basic earnings per share for 2024 were ¥0.06, a decrease of 40.00% compared to ¥0.10 in 2023[6]. - Total assets at the end of 2024 were ¥985,730,497.97, down 13.89% from ¥1,144,706,388.58 at the end of 2023[6]. - The company reported a significant increase in cash outflows from financing activities, totaling ¥144,650,201.74, a rise of 3,970.53% from ¥3,553,592.40[112]. - The company's total revenue for 2024 was approximately ¥763.79 million, a decrease of 16.02% compared to ¥909.51 million in 2023[97]. - Revenue from cardiovascular system drugs was ¥506.48 million, accounting for 66.31% of total revenue, with a year-on-year decline of 22.56%[97]. - Revenue from musculoskeletal system drugs was ¥186.28 million, a slight decrease of 0.95% year-on-year[57]. - Revenue from antiviral respiratory system drugs increased by 24.88% year-on-year, reaching 22.03 million yuan[57]. Product and Market Overview - The company’s main products include four exclusive medical insurance pillar products, which are critical to its revenue[13]. - The company has a total of 162 drug approval numbers, including 15 exclusive products, with a strong product line centered around four major exclusive medical insurance products[37]. - The four major exclusive medical insurance pillar products include 沃华®心可舒片, 骨疏康胶囊/颗粒, 荷丹片/胶囊, and 脑血疏口服液, with varying insurance classifications[45]. - The company has established strong products in the fields of cardiovascular and skeletal chronic diseases, which are expected to benefit from the dual factors of aging and chronic disease prevalence[30]. - The company recognizes the broad prospects of traditional Chinese medicine, leveraging its unique advantages in treating chronic diseases[31]. - The total amount of online procurement orders for traditional Chinese medicine reached CNY 206 billion in 2024, accounting for 2,060 billion of the total CNY 9,962 billion in national procurement orders[34]. - The company’s exclusive products are supported by numerous clinical guidelines and consensus documents, with 沃华®心可舒片 having 33 related documents[45]. Research and Development - The company is focusing on modernizing traditional Chinese medicine through continuous research and development, enhancing product competitiveness and quality control[39]. - The company has established a research institute to attract top talent for new product development and patent registration[47]. - The company’s research and development model includes both independent and collaborative efforts, focusing on innovation and optimization[47]. - The company has obtained a national invention patent certificate for "Lysine Phosphate Calcium Granules and its Preparation Method" during the reporting period[50]. - The company is actively involved in the development of new drugs and secondary product development under national policies supporting traditional Chinese medicine[51]. - The company has developed a rapid detection method for the effective components in Xinkeshu Tablets[50]. - The company is investing in R&D, allocating 100 million yuan towards the development of new technologies and products[165]. Compliance and Governance - The company has established a compliance management system, but risks remain from improper commercial practices by downstream clients or employees[137]. - The company maintains a governance structure that complies with relevant laws and regulations, ensuring independent operations from its controlling shareholder[142]. - The company has established a transparent performance evaluation and incentive mechanism for its directors and senior management[149]. - The audit committee reviewed the 2023 annual financial report and audit report, ensuring compliance with regulatory standards[179]. - The company received a warning letter from the Shandong Securities Regulatory Bureau for violations of information disclosure regulations[171]. - The company has implemented a value management system and disclosed plans for enhancing valuation[138]. Marketing and Sales Strategy - The company has enhanced its marketing strategy by emphasizing online academic promotion and expanding coverage through platforms like JD and Douyin[67]. - The company is focusing on enhancing its marketing strategies by integrating professional clinical promotion with digital marketing initiatives[56]. - The marketing system has been enhanced to cover all terminal categories, with a focus on academic promotion and targeted strategies for different market segments[91]. - The company aims to strengthen its marketing platform by leveraging its four proprietary products to drive sales growth across its entire product range[130]. - The company is committed to expanding its online presence through partnerships with major e-commerce platforms, targeting outpatient markets to create new revenue streams[130]. Risk Management - The company faces risks related to the concentration of its main products and potential policy changes affecting drug pricing and market access, necessitating proactive risk management strategies[134]. - The company acknowledges the risk of intensified market competition in the cardiovascular drug sector, which may threaten sales of its leading products[136]. - The company is actively monitoring potential risks related to changes in actual control due to an ongoing legal dispute involving its major shareholder[137]. - Recent fluctuations in raw material prices have led to an increase in manufacturing costs, impacting the company's normal profit levels[136]. Employee and Management - The total number of employees at the end of the reporting period is 1,089, with 827 from the parent company and 262 from major subsidiaries[185]. - The company implements a performance-oriented compensation and assessment policy, rewarding employees based on individual work performance and professional capabilities[187]. - Employees enjoy benefits such as "five insurances and one fund," paid leave, and paid training, in accordance with national and local policies[187]. - The company has established special rewards for teams and individuals who make outstanding contributions, including overseas travel[187]. - The company has a strong management team with over 30 years of experience in investment and corporate management[160]. Environmental Responsibility - The company adheres to multiple environmental protection laws and regulations, including the Environmental Protection Law of the People's Republic of China and the Water Pollution Prevention and Control Law[200]. - The company is classified as a key pollutant discharge unit by environmental protection authorities[200]. - The company actively engages in clean production initiatives as per the Clean Production Promotion Law of the People's Republic of China[200]. - The company monitors and manages solid waste pollution in accordance with the Solid Waste Pollution Prevention and Control Law[200].

Financial Performance - The company's revenue for Q1 2025 was CNY 217,836,836.34, representing a 1.17% increase compared to CNY 215,317,031.37 in the same period last year[5]. - Net profit attributable to shareholders increased by 136.47% to CNY 22,859,812.88 from CNY 9,667,223.23 year-on-year[5]. - The net profit after deducting non-recurring gains and losses rose by 168.15% to CNY 22,057,608.04 compared to CNY 8,225,848.56 in the previous year[5]. - Total operating revenue for the current period is $217.84 million, an increase from $215.32 million in the previous period, representing a growth of approximately 1.16%[19]. - Operating profit for the current period is $26.10 million, significantly up from $10.65 million in the previous period, marking an increase of approximately 144.61%[20]. - Net profit for the current period is $22.11 million, compared to $8.76 million in the previous period, reflecting a growth of around 151.36%[20]. - Basic and diluted earnings per share both increased to $0.04 from $0.02, a 100% increase[21]. Assets and Liabilities - The company's total assets increased by 3.45% to CNY 1,019,778,595.34 from CNY 985,730,497.97 at the end of the previous year[5]. - Current assets rose to CNY 585,761,028.62, up from CNY 543,118,402.76, indicating an increase of about 7.9%[15]. - Cash and cash equivalents increased to CNY 404,025,624.09 from CNY 344,774,257.71, representing a growth of approximately 17.2%[15]. - Total liabilities increased to CNY 278,652,215.28 from CNY 262,796,323.54, reflecting a growth of about 6.0%[17]. - The company's equity attributable to shareholders rose to CNY 720,228,118.28 from CNY 697,368,305.40, marking an increase of approximately 3.3%[17]. - The company's retained earnings increased to CNY 96,746,369.31 from CNY 73,886,556.43, representing a growth of about 31.0%[17]. - The company’s non-current liabilities decreased to CNY 19,630,708.08 from CNY 20,506,490.20, reflecting a decline of about 4.3%[17]. Cash Flow - Cash flow from operating activities decreased by 11.60% to CNY 48,166,664.21 compared to CNY 54,487,330.32 in the previous year[5]. - Cash flow from operating activities generated a net amount of $48.17 million, down from $54.49 million in the previous period, a decrease of about 11.56%[22]. - The company reported a significant increase in investment cash flow, with a net inflow of CNY 14,591,250.00 compared to a net outflow of CNY 119,485.74 in the same period last year, marking a 12,311.71% change[9]. - The company recorded a net cash inflow from investment activities of $14.59 million, compared to a net outflow of $119.49 thousand in the previous period[23]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 34,476, with the largest shareholder holding 50.27% of the shares[10]. Expenses - Research and development expenses increased to $10.27 million from $8.52 million, an increase of about 20.54%[20]. - The company reported a tax expense of $3.98 million, up from $2.01 million, indicating a rise of approximately 97.56%[20]. Other Financial Metrics - The weighted average return on equity improved to 3.23%, up from 1.19% in the same period last year, reflecting better profitability[5]. - The company's basic and diluted earnings per share both doubled to CNY 0.04 from CNY 0.02 in the previous year[5]. - The company experienced a 32.02% increase in prepaid accounts due to higher material procurement payments during the reporting period[9]. - Inventory decreased to CNY 98,562,497.96 from CNY 107,134,043.15, indicating a decline of approximately 8.5%[15]. - The company reported a decrease in contract liabilities to CNY 2,364,396.69 from CNY 6,850,350.20, indicating a decline of approximately 65.5%[16].